CZP treatment was associated with higher Week @ ACR@ responses versus placebo ( with non-MTX disease modifying antirheumatic drugs -LSB- DMARDs -RSB- , @ % vs. @ % ; without -LSB- monotherapy -RSB- , @ % vs. @ % ) and inhibition of radiographic progression at Week @ ( mTSS CFB ; with non-MTX DMARDs , @ vs. @ ; monotherapy , @ vs. @ ) .